Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes.
(2016) In Drug Metabolism and Pharmacokinetics 31(1). p.3-11- Abstract
- A strong demand in drug discovery and development today is to overcome "Big Gaps" encountered by differences in species and races, to accelerate effective developments in cost and time, and to meet medical needs. Moreover, drugs of various types have emerged which cover middle-size molecules and polymers rather than conventional small molecules. Upon those challenges, mass spectrometry (MS)-based technologies, which will be described in this paper, will play an increasingly important role, among which the liquid chromatography-tandem mass spectrometry (LC/MS/MS) platform will be powerful as rapid and molecule-based analysis more than ever. nanoPore Optical Interferometry (nPOI) newly introduced can detect even weak interactions in... (More)
- A strong demand in drug discovery and development today is to overcome "Big Gaps" encountered by differences in species and races, to accelerate effective developments in cost and time, and to meet medical needs. Moreover, drugs of various types have emerged which cover middle-size molecules and polymers rather than conventional small molecules. Upon those challenges, mass spectrometry (MS)-based technologies, which will be described in this paper, will play an increasingly important role, among which the liquid chromatography-tandem mass spectrometry (LC/MS/MS) platform will be powerful as rapid and molecule-based analysis more than ever. nanoPore Optical Interferometry (nPOI) newly introduced can detect even weak interactions in protein-protein and protein-compound, and can be connected directly to LC/MS/MS for identification of binding molecular species, which will be quite useful for affinity ranking and high-throughput interaction screening. Imaging MS provides the molecular information and spatial distribution of targeted molecules within a tissue specimen. MS-based clinical proteomics utilizing clinical specimens and empowered by advanced bioinformatics can attain both key protein-protein interaction (PPI) networks with major protein players responsible for functional mechanisms of a disease subtype. An integration of those MS-based technologies will deliver a seamless platform of drug development from molecules identified in human clinical specimens. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8577059
- author
- Nakayama, Noboru ; Bando, Yasuhiko ; Fukuda, Tetsuya ; Kawamura, Takeshi ; Nakamura, Haruhiko ; Marko-Varga, György LU and Nishimura, Toshide LU
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Drug Metabolism and Pharmacokinetics
- volume
- 31
- issue
- 1
- pages
- 3 - 11
- publisher
- Japanese Society for the Study of Xenobiotics
- external identifiers
-
- pmid:26782309
- scopus:84957968459
- wos:000369948600002
- pmid:26782309
- ISSN
- 1347-4367
- DOI
- 10.1016/j.dmpk.2015.11.008
- language
- English
- LU publication?
- yes
- id
- 37a14563-6873-44e6-84a2-613819b2bfc4 (old id 8577059)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26782309?dopt=Abstract
- date added to LUP
- 2016-04-04 07:42:01
- date last changed
- 2022-04-23 08:34:31
@article{37a14563-6873-44e6-84a2-613819b2bfc4,
abstract = {{A strong demand in drug discovery and development today is to overcome "Big Gaps" encountered by differences in species and races, to accelerate effective developments in cost and time, and to meet medical needs. Moreover, drugs of various types have emerged which cover middle-size molecules and polymers rather than conventional small molecules. Upon those challenges, mass spectrometry (MS)-based technologies, which will be described in this paper, will play an increasingly important role, among which the liquid chromatography-tandem mass spectrometry (LC/MS/MS) platform will be powerful as rapid and molecule-based analysis more than ever. nanoPore Optical Interferometry (nPOI) newly introduced can detect even weak interactions in protein-protein and protein-compound, and can be connected directly to LC/MS/MS for identification of binding molecular species, which will be quite useful for affinity ranking and high-throughput interaction screening. Imaging MS provides the molecular information and spatial distribution of targeted molecules within a tissue specimen. MS-based clinical proteomics utilizing clinical specimens and empowered by advanced bioinformatics can attain both key protein-protein interaction (PPI) networks with major protein players responsible for functional mechanisms of a disease subtype. An integration of those MS-based technologies will deliver a seamless platform of drug development from molecules identified in human clinical specimens.}},
author = {{Nakayama, Noboru and Bando, Yasuhiko and Fukuda, Tetsuya and Kawamura, Takeshi and Nakamura, Haruhiko and Marko-Varga, György and Nishimura, Toshide}},
issn = {{1347-4367}},
language = {{eng}},
number = {{1}},
pages = {{3--11}},
publisher = {{Japanese Society for the Study of Xenobiotics}},
series = {{Drug Metabolism and Pharmacokinetics}},
title = {{Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes.}},
url = {{http://dx.doi.org/10.1016/j.dmpk.2015.11.008}},
doi = {{10.1016/j.dmpk.2015.11.008}},
volume = {{31}},
year = {{2016}},
}